BR112023017213A2 - Vetores lentivirais direcionados a linfócitos - Google Patents
Vetores lentivirais direcionados a linfócitosInfo
- Publication number
- BR112023017213A2 BR112023017213A2 BR112023017213A BR112023017213A BR112023017213A2 BR 112023017213 A2 BR112023017213 A2 BR 112023017213A2 BR 112023017213 A BR112023017213 A BR 112023017213A BR 112023017213 A BR112023017213 A BR 112023017213A BR 112023017213 A2 BR112023017213 A2 BR 112023017213A2
- Authority
- BR
- Brazil
- Prior art keywords
- lentiviral vectors
- lymphocytes
- vectors targeting
- targeting
- methods
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 5
- 230000008685 targeting Effects 0.000 title abstract 4
- 210000004698 lymphocyte Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
Abstract
vetores lentivirais direcionados a linfócitos. a presente invenção refere-se a vetores lentivirais compreendendo uma proteína de envelope heteróloga mutada, uma proteína de direcionamento e pelo menos um transgene para distribuição e expressão por uma célula caracterizada pela proteína de direcionamento. também são fornecidos métodos e materiais para produzir os vetores lentivirais descritos neste documento, métodos para transduzir células-alvo e células transduzidas por vetores lentivirais de acordo com a presente divulgação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163154639P | 2021-02-26 | 2021-02-26 | |
PCT/US2022/018027 WO2022183072A1 (en) | 2021-02-26 | 2022-02-25 | Lymphocyte targeted lentiviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023017213A2 true BR112023017213A2 (pt) | 2023-11-21 |
Family
ID=80780729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023017213A BR112023017213A2 (pt) | 2021-02-26 | 2022-02-25 | Vetores lentivirais direcionados a linfócitos |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4298114A1 (pt) |
JP (1) | JP2024507996A (pt) |
KR (1) | KR20230160242A (pt) |
CN (1) | CN117203223A (pt) |
AU (1) | AU2022227021A1 (pt) |
BR (1) | BR112023017213A2 (pt) |
CA (1) | CA3212006A1 (pt) |
IL (1) | IL305411A (pt) |
WO (1) | WO2022183072A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114884A2 (en) | 2021-12-15 | 2023-06-22 | Interius Biotherapeutics, Inc. | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
CN116987157B (zh) * | 2023-09-27 | 2023-11-28 | 深圳华大生命科学研究院 | 一种弹状病毒包膜蛋白、含其的靶向慢病毒载体及其应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (pt) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
PE20140100A1 (es) | 2007-09-12 | 2014-02-12 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos |
CN101909631B (zh) | 2007-10-25 | 2012-09-12 | 健泰科生物技术公司 | 制备噻吩并嘧啶化合物的方法 |
CA3177394A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
US20200371088A1 (en) * | 2019-05-23 | 2020-11-26 | Massachusetts Institute Of Technology | Ligand discovery and gene delivery via retroviral surface display |
-
2022
- 2022-02-25 CA CA3212006A patent/CA3212006A1/en active Pending
- 2022-02-25 WO PCT/US2022/018027 patent/WO2022183072A1/en active Application Filing
- 2022-02-25 KR KR1020237030416A patent/KR20230160242A/ko unknown
- 2022-02-25 EP EP22710865.1A patent/EP4298114A1/en active Pending
- 2022-02-25 IL IL305411A patent/IL305411A/en unknown
- 2022-02-25 BR BR112023017213A patent/BR112023017213A2/pt unknown
- 2022-02-25 AU AU2022227021A patent/AU2022227021A1/en active Pending
- 2022-02-25 JP JP2023552220A patent/JP2024507996A/ja active Pending
- 2022-02-25 CN CN202280028023.6A patent/CN117203223A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4298114A1 (en) | 2024-01-03 |
KR20230160242A (ko) | 2023-11-23 |
AU2022227021A1 (en) | 2023-09-21 |
CN117203223A (zh) | 2023-12-08 |
CA3212006A1 (en) | 2022-09-01 |
IL305411A (en) | 2023-10-01 |
WO2022183072A1 (en) | 2022-09-01 |
JP2024507996A (ja) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023017213A2 (pt) | Vetores lentivirais direcionados a linfócitos | |
PH12019502774A1 (en) | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION | |
CL2017002199A1 (es) | Vectores retrovirales a lentivirales | |
MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
CY1121657T1 (el) | Μεθοδοι και συνθεσεις για κατευθυνομενη απο rna τροποποιηση dna στοχου και για κατευθυνομενη απο rna ρυθμιση της μεταγραφης | |
AR123197A2 (es) | Polipéptido aislado que posee actividad pesticida, composición, molécula de adn, célula huésped, construcción, vector, métodos para producirlos y métodos para proteger plantas contra plagas | |
WO2018081789A8 (en) | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion | |
MX2020000244A (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. | |
AU2016256582A8 (en) | Oncolytic adenovirus encoding a B7 protein | |
DK2061891T3 (da) | Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil | |
BRPI0514680A (pt) | produção de anticorpos anti-amilóide beta | |
MX2023005612A (es) | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. | |
BR112021023353A2 (pt) | Método de triagem de uma população de células, retrovírus, método de liberação de um ácido nucleico para uma célula, método para detectar uma interação entre um retrovírus e uma célula, biblioteca de retrovírus, e, população de células | |
BR112018012826A2 (pt) | método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 | |
WO2020163365A3 (en) | Combination gene targets for improved immunotherapy | |
BR112015011466A8 (pt) | Célula hospedeira fúngica recombinante, constructo de ácido nucleico recombinante, sequência de polpeptídeo isolada, e, métodos para produzir um produto de fermentação e pelo menos um produto final a partir de pelo menos um substrato celulósico | |
BR112021024127A2 (pt) | Adenovírus modificado | |
BR112021018734A2 (pt) | Receptores de células t e métodos de uso destes | |
WO2021011936A3 (en) | Cell-type selective immunoprotection of cells | |
BR112022011271A2 (pt) | Célula hospedeira recombinante, composição, métodos para produzir um derivado de uma célula e um produto de fermentação, e, uso de uma célula hospedeira recombinante | |
MX2022011366A (es) | Composiciones y métodos para modificar un ácido nucleico diana. | |
AR110908A1 (es) | Constructo promotor para la síntesis de proteínas libre de células | |
BR112022005963A2 (pt) | Células com expressão de transgenes sustentada | |
AU2018261637A1 (en) | Improved lentiviruses for transduction of hematopoietic stem cells. |